title: Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease.
abstract: OBJECTIVE
  High-dose therapy and autologous bone marrow transplantation (ABMT) are being increasingly utilized for the management of patients with relapsed Hodgkin's disease. Because patients with relapsed Hodgkin's disease often initially respond to salvage chemotherapy regimens, ABMT is frequently delayed until late in the course of the disease. The optimal timing for ABMT has not been identified. The purpose of this study was to determine the value of ABMT earlier in the course of Hodgkin's disease.
  
  
  METHODS
  We treated 70 patients between October 1984 and October 1988 with high-dose cyclophosphamide, carmustine, and etoposide, followed by infusion of previously cryopreserved autologous bone marrow, and analyzed the results to determine the impact of timing of ABMT on treatment outcome. One (17 patients), two (24 patients), or three or more (29 patients) chemotherapy regimens had failed in patients before ABMT.
  
  
  RESULTS
  The results for all 70 patients included a complete remission rate of 59%, an early death rate of 11%, a 4-year survival of 47%, and 27% of all treated patients alive and in complete remission at 4 years. The median follow-up for patients remaining in complete remission is 56 months (range 26 to 73 months). The frequency of achieving a complete remission was higher in patients in whom fewer regimens had failed before ABMT (i.e., 82% versus 58% versus 45%, p = 0.02), as was the 4-year disease-free survival (i.e., 44% versus 33% versus 21%, p = 0.04).
  
  
  CONCLUSIONS
  ABMT is a more effective therapy when used early for patients with relapsed Hodgkin's disease.
authors.affiliation: Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198-3330.
authors.forename: J O
authors.initials: JO
authors.lastname: Armitage
authors.forename: P J
authors.initials: PJ
authors.lastname: Bierman
authors.forename: J M
authors.initials: JM
authors.lastname: Vose
authors.forename: J R
authors.initials: JR
authors.lastname: Anderson
authors.forename: D D
authors.initials: DD
authors.lastname: Weisenburger
authors.forename: A
authors.initials: A
authors.lastname: Kessinger
authors.forename: E C
authors.initials: EC
authors.lastname: Reed
authors.forename: W P
authors.initials: WP
authors.lastname: Vaughan
authors.forename: P F
authors.initials: PF
authors.lastname: Coccia
authors.forename: D T
authors.initials: DT
authors.lastname: Purtilo
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D015996:Survival Rate; D014182:Transplantation, Autologous